Clinical Trial Update: Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI) [Phase 2]

View source ↗

Summary

Phase 2 trial update for Penn Microbiome Therapy (PMT) in severe Clostridioides difficile infection, with termination and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection
• Severe-complicated Fulminant Clostridium Difficile Infection

Drugs mentioned

• Penn Microbiome Therapy (PMT)

Snippet

Sponsor: University of Pennsylvania | Conditions: Severe Clostridium Difficile Infection, Severe-Complicated/Fulminant Clostridium Difficile Infection | Phase 2 | Status: TERMINATED | Results posted: 2023-10-30